MaineCare Bulletins

MaineCare Notice of Agency Rule-making Adoption, MaineCare Benefits Manual, Chapters II and III, Section 45 State & Federal Policy
Novavax Monovalent COVID-19 Vaccine Authorized for Use as Booster Doses in Adults Ages 18 and Older General Notifications for All Providers
Atrezzo Upgrade General Notifications for All Providers
Proposed Rate Determination Schedule General Notifications for All Providers
Attention Section 45, Hospital Services Providers Hospital & Clinic Services
Update to Providers Participating in the 340B Drug Program, CR 112772 General Notifications for All Providers
Crown PA Exception for Endodontic Therapy, CR 112997 Dental Services
Pfizer and Moderna Bivalent COVID-19 Vaccines Authorized to Use as Booster Doses in Children Ages Five Years and Older General Notifications for All Providers
Rate Determination Initiation Notice for Section 107, Psychiatric Residential Treatment Facility Services  Behavioral Health (BH)
LD 1262: Public Stakeholder Sessions for a Statewide Strategic Plan to Serve Maine People with Behavioral Health Needs Throughout Their Lifespans Behavioral Health (BH)
Rate Determination Initiation Notice for Section 23 Developmental and Behavioral Health Services – New Service: Foster Care Comprehensive Health Assessment   Behavioral Health (BH)
PCPlus Application now Open General Notifications for All Providers
Attn: Providers Participating in the 340B Drug Program, CR 112772 General Notifications for All Providers
Rate Determination Initiation Notice for Section 45 Hospital Services  Hospital & Clinic Services
Updates to Hospital and Pregnancy Presumptive Eligibility Display Hospital, Family Planning, and Ambulatory Care/Clinic Services
Atrezzo Upgrade General Notifications for All Providers
340B Provider Enrollment Guidance General Notifications for All Providers
Maine Department of Health and Human Services Certified Community Behavioral Health Clinic Stakeholder Meeting Series General Notifications for All Providers
MaineCare Notice of Agency Waiver Amendment State & Federal Policy
Clarification of Biosimilar Ocular Use  Specialty Services